© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
Case–Control Study of Simian Virus 40 and Non-Hodgkin Lymphoma in the United States
Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Rockville, MD (EAE, SDS, JSC, PH); Johns Hopkins University School of Medicine, Baltimore, MD (RPV); Fred Hutchinson Cancer Research Center, Seattle, WA (DAG, JJC, SD); Mayo Clinic, Rochester, MN (JRC); University of Southern California, Los Angeles (WC); Karmanos Cancer Institute, Wayne State University, Detroit, MI (RKS); Institut Catala d'Oncologia, Barcelona, Spain (SDS)
Correspondence to: Eric A. Engels, MD, MPH, Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., EPS 8010, Rockville, MD 20892 (e-mail: engelse{at}exchange.nih.gov)
Background: Recent studies have reported detection of simian virus 40 (SV40) DNA in tumor tissues from 15%–43% of U.S. non-Hodgkin lymphoma (NHL) patients. SV40 accidentally contaminated U.S. poliovirus vaccines that were widely administered from 1955 through 1962. However, epidemiologic data linking SV40 with NHL are lacking. Methods: We obtained serum samples from 724 incident NHL case patients and 622 control subjects from a population-based U.S. case–control study. SV40 serostatus was analyzed by two independent laboratories (designated A and B) using similar virus-like particle (VLP) enzyme immunoassays. Associations with serostatus were assessed with logistic regression, adjusting for sex, race, birth year, and study site. VLPs for the human polyomaviruses BK and JC were used in competitive inhibition experiments to assess the specificity of SV40 reactivity. Statistical tests were two-sided. Results: SV40 antibody results from the two laboratories were correlated (R = 0.59; P<.001). Laboratories A and B detected SV40 seropositivity in 7.2% and 9.8% of NHL case patients, respectively, and in 10.5% and 9.6% of control subjects, respectively. SV40 seropositivity was not associated with increased NHL risk (laboratory A: adjusted odds ratio [OR] = 0.68, 95% confidence interval [CI] = 0.46 to 1.00; laboratory B: adjusted OR = 1.02, 95% CI = 0.71 to 1.47). SV40 seropositivity was not associated with NHLs of any specific histology or site. Among subjects born before 1963, 1.0%–1.6% showed SV40-specific reactivity, i.e., SV40 reactivity confirmed in competitive inhibition experiments, whereas (based on limited data) none born subsequently demonstrated SV40-specific reactivity. Conclusions: In persons born before 1963, the presence of SV40-specific antibodies, although rare, could reflect exposure to SV40-contaminated vaccines. Nevertheless, NHL risk was unrelated to serologic evidence of SV40 exposure or infection.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: Simian Virus 40 Not Associated With Non-Hodgkin Lymphoma, Study Shows
- Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1347.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  P. Randhawa, R. Viscidi, J. J. Carter, D. A. Galloway, T. D. Culp, C. Huang, B. Ramaswami, and N. D. Christensen Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies J. Gen. Virol., March 1, 2009; 90(3): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Poulin and J. A. DeCaprio Is There a Role for SV40 in Human Cancer? J. Clin. Oncol., September 10, 2006; 24(26): 4356 - 4365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Randhawa, G. Gupta, A. Vats, R. Shapiro, and R. P. Viscidi Immunoglobulin G, A, and M Responses to BK Virus in Renal Transplantation Clin. Vaccine Immunol., September 1, 2006; 13(9): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. De Roos, P. Hartge, J. H. Lubin, J. S. Colt, S. Davis, J. R. Cerhan, R. K. Severson, W. Cozen, D. G. Patterson Jr., L. L. Needham, et al. Persistent Organochlorine Chemicals in Plasma and Risk of Non-Hodgkin's Lymphoma Cancer Res., December 1, 2005; 65(23): 11214 - 11226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lundstig, L. Eliasson, M. Lehtinen, K. Sasnauskas, P. Koskela, and J. Dillner Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles J. Gen. Virol., June 1, 2005; 86(6): 1703 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Rollison, K. J. Helzlsouer, N. A. Halsey, K. V. Shah, and R. P. Viscidi Markers of Past Infection with Simian Virus 40 (SV40) and Risk of Incident Non-Hodgkin Lymphoma in a Maryland Cohort Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1448 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Engels, J. Chen, P. Hartge, J. R. Cerhan, S. Davis, R. K. Severson, W. Cozen, and R. P. Viscidi Antibody Responses to Simian Virus 40 T Antigen: A Case-Control Study of Non-Hodgkin Lymphoma Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 521 - 524. [Abstract] [Full Text] [PDF]
|
|